{"id":3201,"date":"2025-08-08T13:41:33","date_gmt":"2025-08-08T13:41:33","guid":{"rendered":"https:\/\/healthscience.institute\/?p=3201"},"modified":"2025-12-09T07:48:10","modified_gmt":"2025-12-09T07:48:10","slug":"who-obesity-drug-decision-wegovy","status":"publish","type":"post","link":"https:\/\/staging.scienceinhealth.com\/de\/who-obesity-drug-decision-wegovy\/","title":{"rendered":"Keine Adipositas-Medikamente in der Liste der unentbehrlichen Arzneimittel der WHO"},"content":{"rendered":"\n<p><strong>Key Points<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>WHO excluded all obesity drugs, including semaglutide (Wegovy), from its 2023 Essential Medicines List (EML).<\/li>\n\n\n\n<li>The decision has reignited global debate over whether obesity should be treated as a medical issue or addressed with broader public health strategies.<\/li>\n\n\n\n<li>Supporters of inclusion cite compelling weight-loss and cardiovascular outcomes; critics point to cost, equity, and long-term data gaps.<\/li>\n\n\n\n<li>WHO prioritized scalable, prevention-first solutions over expensive drug-based interventions.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<p>In 2023, the World Health Organization made a headline-grabbing decision: it declined to include any obesity drugs\u2014most notably, semaglutide (marketed as Wegovy)\u2014in its latest update of the Essential Medicines List (EML)<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#1\">\u00b9<\/a>. This list, revised every two years, serves as a benchmark for which therapies governments and global health systems should prioritize.<\/p>\n\n\n\n<p>For many, this felt like a step backward. Obesity is linked to higher risks of blood sugar regulation problems, heart problems, joint pain, and certain cancers. Why would the WHO sideline a category of therapies that, by several accounts, could improve quality of life and reduce mortality?<\/p>\n\n\n\n<p>The answer lies in a layered mix of cost-effectiveness, public health strategy, and ethical questions about what it truly means to \u201ctreat\u201d obesity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Why the Decision Matters<\/strong><\/h2>\n\n\n\n<p>Obesity is now one of the most urgent public health challenges worldwide. More than 1 billion people live with obesity, including nearly 160 million children and adolescents<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#2\">\u00b2<\/a>. Beyond visible weight gain, the symptom is associated with elevated risk for noncommunicable diseases (NCDs) such as type 2 blood sugar regulation problems, heart problems, and some cancers.<\/p>\n\n\n\n<p>The WHO Essential Medicines List was created to help countries, especially those with limited healthcare infrastructure, prioritize therapies that offer the greatest impact per dollar. Inclusion on the list boosts global access, funding, and regulatory support.But in its 2023 decision, the WHO expert committee concluded that obesity medications\u2014including GLP-1 receptor agonists like semaglutide and liraglutide\u2014\u201cdid not meet the criteria for inclusion\u201d<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#3\">\u00b3<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What the WHO Cited<\/strong><\/h2>\n\n\n\n<p>According to the WHO\u2019s official report, the reasons for rejection included:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>High cost and low affordability, especially in low- and middle-income countries<\/li>\n\n\n\n<li>Limited long-term data on outcomes, safety, and user adherence<\/li>\n\n\n\n<li>Concerns about widespread off-label or cosmetic use<\/li>\n\n\n\n<li>Inadequate evidence of population-level impact in real-world settings<\/li>\n<\/ul>\n\n\n\n<p>The committee noted that while GLP-1 drugs had shown weight loss benefits in studies, they were not yet proven to offer long-term reductions in mortality or complications when used for obesity alone. Until those data are clearer\u2014and until costs come down\u2014the drugs remain outside WHO\u2019s global priorities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What the Science Actually Shows<\/strong><\/h2>\n\n\n\n<p>Semaglutide is part of a class of injectable therapies that mimic GLP-1, a hormone involved in appetite regulation and insulin release. A landmark 2021 trial published in <em>The New England Journal of Medicine<\/em> found that users of semaglutide lost, on average, 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#4\">\u2074<\/a>. Other studies have shown potential cardiovascular benefits, such as reduced risk of heart problems in those with obesity and no prior diagnosis of blood sugar regulation issues<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#5\">\u2075<\/a>.<\/p>\n\n\n\n<p>Yet these benefits come at a price\u2014literally. Monthly retail costs for semaglutide exceed $1,000 in the U.S., and access in lower-income regions is virtually nonexistent. Additionally, users often experience gastrointestinal symptoms, and many regain weight after discontinuing the therapy<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#6\">\u2076<\/a>.<\/p>\n\n\n\n<p><strong><a href=\"http:\/\/scienceinhealth.com\/newsletter\/\">Subscribe for Free for more insightful health articles tailored to your needs.<\/a><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Pharma Pressure and Ethical Tensions<\/strong><\/h2>\n\n\n\n<p>Many critics see the push for inclusion on the EML as not only scientific but also commercial. Novo Nordisk, the manufacturer of Wegovy and Ozempic, has aggressively lobbied for global recognition and reimbursement of semaglutide.<\/p>\n\n\n\n<p>A <em>BMJ<\/em> investigation noted that some of the experts involved in recommending GLP-1 inclusion had industry ties, raising questions about impartiality<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#7\">\u2077<\/a>. At the heart of the concern is the possibility that the EML could be influenced more by pharma marketing than by equitable health priorities.<\/p>\n\n\n\n<p>As WHO officials put it, the EML is \u201cnot a recognition of scientific promise alone\u2014it\u2019s a guide for what works, what\u2019s needed, and what\u2019s possible at scale\u201d<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#3\">\u00b3<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Framing Obesity: Disease or Social Symptom?<\/strong><\/h2>\n\n\n\n<p>The WHO\u2019s decision underscores a long-running debate: Should obesity be treated primarily through medical interventions\u2014or through social, environmental, and behavioral reforms?<\/p>\n\n\n\n<p>High-income countries like the U.S. and UK tend to frame obesity as a chronic, biological symptom. Accordingly, their regulatory agencies\u2014the FDA and EMA\u2014have approved semaglutide for chronic weight management<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#8\">\u2078<\/a>.<\/p>\n\n\n\n<p>The WHO takes a broader view, emphasizing population-level prevention. Its 2022 report on obesity called for sugar taxes, urban design reforms, food advertising restrictions, and nutrition education as first-line strategies<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#9\">\u2079<\/a>.<\/p>\n\n\n\n<p>These measures are often more scalable and cost-effective than individual therapy, especially in nations where people still struggle to access basic health services.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Equity and Access: The Crux of the Debate<\/strong><\/h2>\n\n\n\n<p>Excluding obesity drugs from the EML may frustrate users in wealthy countries, but for many public health experts, it\u2019s a pragmatic move. The cost of delivering injectable drugs globally is massive. Cold-chain storage, regular injections, and physician supervision make widespread rollout unlikely in rural or under-resourced communities.<\/p>\n\n\n\n<p>Dr. Francesco Branca, WHO\u2019s director of nutrition and food safety, summed it up clearly: \u201cWe must focus on solutions that are practical and equitable for every population\u2014not just the ones that can afford it\u201d<a href=\"https:\/\/chatgpt.com\/g\/g-p-681b06bfb1d8819183a88d8038d75377-hsi\/c\/6880d059-5ffc-800d-bbc5-e151210348ee#3\">\u00b3<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Where Do We Go from Here?<\/strong><\/h2>\n\n\n\n<p>Although obesity drugs aren\u2019t currently on the EML, this may not be the final word. The WHO left open the possibility of reconsidering the issue if future studies show long-term benefits, improved affordability, and population-level outcomes.<\/p>\n\n\n\n<p>In the meantime, countries can\u2014and some already do\u2014include semaglutide in their national essential medicines lists. But the WHO&#8217;s stance sends a strong signal: addressing obesity requires more than a prescription.<\/p>\n\n\n\n<p>It demands a system-wide reimagining of food environments, social norms, economic structures, and public policy. And for now, the world\u2019s most influential health body has decided that\u2019s where the real work begins.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>References<\/strong><\/h2>\n\n\n\n<p>1. World Health Organization. WHO Model List of Essential Medicines \u2013 2023 edition.<a href=\"https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.01\">Link<br><\/a> 2. WHO Obesity and Overweight Fact Sheet, 2023.<a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight\">Link<br><\/a> 3. WHO Expert Committee on the Selection and Use of Essential Medicines. 2023 Report.<a href=\"https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.01\">Link<br><\/a> 4. Wilding JPH, et al. \u201cOnce-Weekly Semaglutide in Adults with Overweight or Obesity.\u201d <em>New England Journal of Medicine<\/em>, 2021.<a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\">DOI<br><\/a> 5. Lincoff AM, et al. \u201cSemaglutide and Cardiovascular Outcomes in Obesity.\u201d <em>NEJM<\/em>, 2023.<a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2307563\">DOI<br><\/a> 6. Rubino D, et al. \u201cWeight Regain and Discontinuation of GLP-1 Therapy.\u201d <em>Lancet Diabetes Endocrinol<\/em>, 2022.<br>7. Abbasi J. \u201cWHO Rejects Obesity Drug Amid Industry Pressure Concerns.\u201d <em>The BMJ<\/em>, 2023.<a href=\"https:\/\/www.bmj.com\/content\/380\/bmj.p942\">Link<br><\/a> 8. FDA Approval for Wegovy (Semaglutide) for Chronic Weight Management.<a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management\">FDA.gov<br><\/a> 9. WHO Acceleration Plan to Stop Obesity, 2022.<a href=\"https:\/\/www.who.int\/publications\/i\/item\/9789240057733\">Link<\/a><br>10. World Health Organization. (2024, September 25). <em>Essential medicines<\/em>. WHO Fact Sheet. <a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/essential-medicines\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/essential-medicines<\/a><br>11. World Health Organization. (2025, May 7). <em>Obesity and overweight<\/em>. WHO Fact Sheet. <a href=\"https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight\">https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight<\/a><br>12. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. <em>New England Journal of Medicine, 384<\/em>(11), 989\u20131002. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2032183\">https:\/\/doi.org\/10.1056\/NEJMoa203218<\/a><br>13. Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity. <em>New England Journal of Medicine, 389<\/em>(24), 2221\u20132232. <a href=\"https:\/\/doi.org\/10.1056\/NEJMoa2307563\">https:\/\/doi.org\/10.1056\/NEJMoa2307563<\/a><br>14. World Health Organization. (2022, March 4). <em>World Obesity Day 2022 \u2013 Accelerating action to stop obesity<\/em> [Press release]. <a href=\"https:\/\/www.who.int\/news\/item\/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity\">https:\/\/www.who.int\/news\/item\/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity<\/a><br>15. International Diabetes Federation (Europe). (2025, September 6). <em>WHO expands essential medicines list<\/em>. <a href=\"https:\/\/idf.org\/europe\/news\/who-expands-essential-medicines-list\/\">https:\/\/idf.org\/europe\/news\/who-expands-essential-medicines-list\/<\/a><\/p>\n\n\n\n<ol class=\"wp-block-list\"><\/ol>\n\n\n\n<p><em>The article does not in any way constitute as medical advice. Please seek consultation with a licensed medical professional before starting any treatment. This website may receive commissions from the links or products mentioned in this article.<\/em><\/p>\n\n\n\n<p><strong><a href=\"http:\/\/scienceinhealth.com\/newsletter\/\">Subscribe for Free for more insightful health articles tailored to your needs.<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Points In 2023, the World Health Organization made a headline-grabbing decision: it declined to include any obesity drugs\u2014most&hellip;<\/p>","protected":false},"author":13,"featured_media":3202,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24,18],"tags":[300,299,301],"class_list":["post-3201","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology-in-medicine","category-health-tech","tag-anti-obesity-medications","tag-obesity-drugs-who","tag-who"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Why WHO Excluded Obesity Drugs Like Wegovy from Key List<\/title>\n<meta name=\"description\" content=\"WHO left obesity drugs like semaglutide (Wegovy) off its 2023 Essential Medicines List. Here\u2019s what it means for global health, access, and obesity treatment policy.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Why WHO Excluded Obesity Drugs Like Wegovy from Key List\" \/>\n<meta property=\"og:description\" content=\"WHO left obesity drugs like semaglutide (Wegovy) off its 2023 Essential Medicines List. Here\u2019s what it means for global health, access, and obesity treatment policy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/staging.scienceinhealth.com\/de\/who-obesity-drug-decision-wegovy\/\" \/>\n<meta property=\"og:site_name\" content=\"Health Science Institute\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-08T13:41:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-09T07:48:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/staging.scienceinhealth.com\/wp-content\/uploads\/2025\/07\/WHO-Essential-Medicines-List.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"768\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Dr Anne Therese Bernadette Laudato, MD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr Anne Therese Bernadette Laudato, MD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"6\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/\"},\"author\":{\"name\":\"Dr Anne Therese Bernadette Laudato, MD\",\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/#\\\/schema\\\/person\\\/7ce8dda369f9cddd401a3b4c4778153b\"},\"headline\":\"No Obesity Drugs in WHO Essential Medicines List\",\"datePublished\":\"2025-08-08T13:41:33+00:00\",\"dateModified\":\"2025-12-09T07:48:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/\"},\"wordCount\":1255,\"commentCount\":2,\"publisher\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/WHO-Essential-Medicines-List.webp\",\"keywords\":[\"anti-obesity medications\",\"obesity drugs WHO\",\"WHO\"],\"articleSection\":[\"Biotechnology in Medicine\",\"Health Tech\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/#respond\"]}]},{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/\",\"url\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/\",\"name\":\"Why WHO Excluded Obesity Drugs Like Wegovy from Key List\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/WHO-Essential-Medicines-List.webp\",\"datePublished\":\"2025-08-08T13:41:33+00:00\",\"dateModified\":\"2025-12-09T07:48:10+00:00\",\"description\":\"WHO left obesity drugs like semaglutide (Wegovy) off its 2023 Essential Medicines List. Here\u2019s what it means for global health, access, and obesity treatment policy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/WHO-Essential-Medicines-List.webp\",\"contentUrl\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/WHO-Essential-Medicines-List.webp\",\"width\":768,\"height\":512},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/fr\\\/who-obesity-drug-decision-wegovy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"No Obesity Drugs in WHO Essential Medicines List\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/\",\"name\":\"Health Science Institute\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/#organization\",\"name\":\"Health Science Institute\",\"url\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/hsi.png\",\"contentUrl\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/hsi.png\",\"width\":800,\"height\":200,\"caption\":\"Health Science Institute\"},\"image\":{\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/#\\\/schema\\\/person\\\/7ce8dda369f9cddd401a3b4c4778153b\",\"name\":\"Dr Anne Therese Bernadette Laudato, MD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ba0b9e09004dfa650ba1fe31ed160918ed0461837f1c600f05f09e7967584938?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ba0b9e09004dfa650ba1fe31ed160918ed0461837f1c600f05f09e7967584938?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ba0b9e09004dfa650ba1fe31ed160918ed0461837f1c600f05f09e7967584938?s=96&d=mm&r=g\",\"caption\":\"Dr Anne Therese Bernadette Laudato, MD\"},\"description\":\"Dr. Anne Therese Bernadette Laudato is a licensed physician with a strong commitment to patient care, public health, and evidence-based medical writing. With a background in both hospital and community settings, she is passionate about making healthcare knowledge more accessible and meaningful to a broader audience.\",\"url\":\"https:\\\/\\\/staging.scienceinhealth.com\\\/de\\\/author\\\/therese\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Why WHO Excluded Obesity Drugs Like Wegovy from Key List","description":"WHO left obesity drugs like semaglutide (Wegovy) off its 2023 Essential Medicines List. Here\u2019s what it means for global health, access, and obesity treatment policy.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"de_DE","og_type":"article","og_title":"Why WHO Excluded Obesity Drugs Like Wegovy from Key List","og_description":"WHO left obesity drugs like semaglutide (Wegovy) off its 2023 Essential Medicines List. Here\u2019s what it means for global health, access, and obesity treatment policy.","og_url":"https:\/\/staging.scienceinhealth.com\/de\/who-obesity-drug-decision-wegovy\/","og_site_name":"Health Science Institute","article_published_time":"2025-08-08T13:41:33+00:00","article_modified_time":"2025-12-09T07:48:10+00:00","og_image":[{"width":768,"height":512,"url":"https:\/\/staging.scienceinhealth.com\/wp-content\/uploads\/2025\/07\/WHO-Essential-Medicines-List.webp","type":"image\/webp"}],"author":"Dr Anne Therese Bernadette Laudato, MD","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Dr Anne Therese Bernadette Laudato, MD","Gesch\u00e4tzte Lesezeit":"6\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/#article","isPartOf":{"@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/"},"author":{"name":"Dr Anne Therese Bernadette Laudato, MD","@id":"https:\/\/staging.scienceinhealth.com\/de\/#\/schema\/person\/7ce8dda369f9cddd401a3b4c4778153b"},"headline":"No Obesity Drugs in WHO Essential Medicines List","datePublished":"2025-08-08T13:41:33+00:00","dateModified":"2025-12-09T07:48:10+00:00","mainEntityOfPage":{"@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/"},"wordCount":1255,"commentCount":2,"publisher":{"@id":"https:\/\/staging.scienceinhealth.com\/de\/#organization"},"image":{"@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/#primaryimage"},"thumbnailUrl":"https:\/\/staging.scienceinhealth.com\/wp-content\/uploads\/2025\/07\/WHO-Essential-Medicines-List.webp","keywords":["anti-obesity medications","obesity drugs WHO","WHO"],"articleSection":["Biotechnology in Medicine","Health Tech"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/#respond"]}]},{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/","url":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/","name":"Why WHO Excluded Obesity Drugs Like Wegovy from Key List","isPartOf":{"@id":"https:\/\/staging.scienceinhealth.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/#primaryimage"},"image":{"@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/#primaryimage"},"thumbnailUrl":"https:\/\/staging.scienceinhealth.com\/wp-content\/uploads\/2025\/07\/WHO-Essential-Medicines-List.webp","datePublished":"2025-08-08T13:41:33+00:00","dateModified":"2025-12-09T07:48:10+00:00","description":"WHO left obesity drugs like semaglutide (Wegovy) off its 2023 Essential Medicines List. Here\u2019s what it means for global health, access, and obesity treatment policy.","breadcrumb":{"@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/#primaryimage","url":"https:\/\/staging.scienceinhealth.com\/wp-content\/uploads\/2025\/07\/WHO-Essential-Medicines-List.webp","contentUrl":"https:\/\/staging.scienceinhealth.com\/wp-content\/uploads\/2025\/07\/WHO-Essential-Medicines-List.webp","width":768,"height":512},{"@type":"BreadcrumbList","@id":"https:\/\/staging.scienceinhealth.com\/fr\/who-obesity-drug-decision-wegovy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/staging.scienceinhealth.com\/"},{"@type":"ListItem","position":2,"name":"No Obesity Drugs in WHO Essential Medicines List"}]},{"@type":"WebSite","@id":"https:\/\/staging.scienceinhealth.com\/de\/#website","url":"https:\/\/staging.scienceinhealth.com\/de\/","name":"Health Science Institute","description":"","publisher":{"@id":"https:\/\/staging.scienceinhealth.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.scienceinhealth.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/staging.scienceinhealth.com\/de\/#organization","name":"Health Science Institute","url":"https:\/\/staging.scienceinhealth.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/staging.scienceinhealth.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/staging.scienceinhealth.com\/wp-content\/uploads\/2024\/07\/hsi.png","contentUrl":"https:\/\/staging.scienceinhealth.com\/wp-content\/uploads\/2024\/07\/hsi.png","width":800,"height":200,"caption":"Health Science Institute"},"image":{"@id":"https:\/\/staging.scienceinhealth.com\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/staging.scienceinhealth.com\/de\/#\/schema\/person\/7ce8dda369f9cddd401a3b4c4778153b","name":"Dr Anne Therese Bernadette Laudato, MD","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/ba0b9e09004dfa650ba1fe31ed160918ed0461837f1c600f05f09e7967584938?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ba0b9e09004dfa650ba1fe31ed160918ed0461837f1c600f05f09e7967584938?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba0b9e09004dfa650ba1fe31ed160918ed0461837f1c600f05f09e7967584938?s=96&d=mm&r=g","caption":"Dr Anne Therese Bernadette Laudato, MD"},"description":"Dr. Anne Therese Bernadette Laudato ist eine zugelassene \u00c4rztin mit einem starken Engagement f\u00fcr Patientenversorgung, \u00f6ffentliche Gesundheit und evidenzbasiertes medizinisches Schreiben. Mit ihrem Hintergrund sowohl im Krankenhaus- als auch im kommunalen Umfeld setzt sie sich leidenschaftlich daf\u00fcr ein, Gesundheitswissen einem breiteren Publikum zug\u00e4nglicher und aussagekr\u00e4ftiger zu machen.","url":"https:\/\/staging.scienceinhealth.com\/de\/author\/therese\/"}]}},"_links":{"self":[{"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/posts\/3201","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/comments?post=3201"}],"version-history":[{"count":1,"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/posts\/3201\/revisions"}],"predecessor-version":[{"id":5545,"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/posts\/3201\/revisions\/5545"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/media\/3202"}],"wp:attachment":[{"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/media?parent=3201"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/categories?post=3201"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.scienceinhealth.com\/de\/wp-json\/wp\/v2\/tags?post=3201"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}